Paper Details

  1. Home
  2. Paper Details

Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study.

Author: EvansRobert R, King-DavisShirletta, KivitzAlan, SchumacherH Ralph, SundyJohn S, WeinsteinSteven P, WuRichard

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rilonacept 160 mg once weekly was safe and significantly reduced the risk of gout flares in patients initiating or continuing urate-lowering therapy.
Paper Details　
Original Abstract of the Article :
OBJECTIVE: To evaluate the safety and efficacy of once-weekly subcutaneous rilonacept 160 mg for prevention of gout flares in patients initiating or continuing urate-lowering therapy (ULT). METHODS: This phase III study was conducted in the United States, South Africa, Europe, and Asia. Adults (n =...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.3899/jrheum.131226

データ提供：米国国立医学図書館（NLM）

Rilonacept: A New Hope for Gout Flare Prevention

Gout is a painful inflammatory condition caused by the buildup of uric acid crystals in the joints. This research explores the potential of rilonacept, a new medication, for preventing gout flares in patients receiving urate-lowering therapy (ULT). The authors conducted a phase III safety study involving 1315 patients with gout, finding that rilonacept significantly reduced the risk of gout flares compared to placebo. While injection-site reactions were more common with rilonacept, the overall safety profile was consistent with previous studies. These findings suggest that rilonacept could be a valuable tool for managing gout and improving patient quality of life.

Rilonacept: A Promising New Treatment for Gout Flare Prevention

The phase III safety study, involving over 1300 patients with gout, demonstrates the efficacy of rilonacept in reducing the risk of gout flares. These findings suggest that rilonacept could be a valuable treatment option for patients with gout, particularly those seeking to reduce the frequency and severity of flares. Further research is needed to explore the long-term safety and efficacy of rilonacept.

Managing Gout: A Collaborative Effort

This study highlights the importance of ongoing research in developing new and effective treatments for gout. The findings suggest that rilonacept could be a valuable addition to the existing arsenal of gout management strategies. Remember, consulting with a qualified healthcare professional is essential for developing a personalized treatment plan based on individual needs and health history.

Dr.Camel's Conclusion

This research offers a beacon of hope in the desert of gout management. The findings suggest that rilonacept could be a valuable tool for preventing gout flares and improving patient quality of life. Just as a camel relies on its resilience to navigate the desert, individuals with gout can find strength and comfort through effective treatment strategies. Remember, working closely with a healthcare professional is crucial for managing gout and achieving a comfortable and fulfilling life.

Date :
  1. Date Completed 2015-04-09
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

25028379

DOI: Digital Object Identifier

10.3899/jrheum.131226

Related Literature

Article Analysis
・Effects of rilonacept injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.